ClinicalTrials.gg
CompletedNCT04964739Updated Nov 12, 2026Results posted

Gender/Sex & CUD Remission

An interventional study of Cognitive Behavioral Therapy (CBT4CBT) in Cannabis Use Disorder, Mild, Cannabis Use Disorder, Moderate and Cannabis Use Disorder, Severe, sponsored by Medical University of South Carolina. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Other

How we know

Updated Nov 12, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
224
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,187 studies in Lymphoma, Follicular with a site in United States — 128 open to participants now, 217 under way, 20 of them phase 3. Lymphoma, Follicular · United States.

Enrollment
118th of 1,017
224 · median 38
Started
2021
with 41 others
No phase
119 of 1,187
18 open now
Registered
1,000th of 1,187
by date

Among the 1,187 studies in Lymphoma, Follicular with a site in United States, this one is the 118th largest by enrollment of the 1,017 interventional ones that give a count, is one of 42 that started in 2021, is one of 119 with no phase, and was the 1,000th registered.

Lymphoma, Follicular

1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

128 of the 1,187 studies in Lymphoma, Follicular with a site in United States are open now. Recruiting first, the newest first:

123 more — sign in →

All 128 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,187 studies in Lymphoma, Follicular with a site in United States, or all of them as a file.
02

Study summary

Adults (ages 18+) who would like to reduce their cannabis use (N=224) will be enrolled in an 8-week treatment program. All participants will receive counseling (1 goals session with a therapist followed by 7 weekly computerized cognitive-behavioral therapy sessions). Detailed cannabis assessments (biological and self-report) will be conducted throughout treatment and at 1-, 2-, and 3-months post-treatment completion. Daily electronic diaries will be administered via text message to record detailed logs of cannabis use quantity and frequency. Salivary samples will be collected (and video observed) daily throughout treatment to analyze for progesterone.

03

Conditions studied

  • Cannabis Use Disorder, Mild
  • Cannabis Use Disorder, Moderate
  • Cannabis Use Disorder, Severe
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willingness to participate in a research study (otherwise, will be referred to appropriate clinical services if seeking clinical care).
  2. Meet current (within last 30 days) criteria for cannabis use disorder.
  3. Submit a positive urine cannabinoid test during screening.
  4. Interested in treatment for cannabis use disorder.

Exclusion criteria

Exclusion Criteria:

  1. Significant or acutely unstable medical or psychiatric problems (i.e., psychosis, mania) that would contraindicate research procedures, interfere with safety, compromise data integrity, or preclude consistent study participation.
  2. The presence of any substance use disorder requiring a higher level of care.
  3. Significant risk of homicide or suicide.
  4. Pregnant, trying to become pregnant, or breastfeeding.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
224 participants (actual)

Study arms

  • Other
    Cognitive Behavioral Therapy - Males

    112 male participants were enrolled in 8 weeks of behavioral treatment for cannabis use disorder (CUD). They received a motivational interviewing session with a therapist followed by 7 weekly online modules of CBT4CBT with continued monitoring and support from a therapist.

    Behavioral: Cognitive Behavioral Therapy (CBT4CBT)

  • Other
    Cognitive Behavioral Therapy - Females

    112 female participants were enrolled in 8 weeks of behavioral treatment for cannabis use disorder (CUD). They received a motivational interviewing session with a therapist followed by 7 weekly online modules of CBT4CBT with continued monitoring and support from a therapist.

    Behavioral: Cognitive Behavioral Therapy (CBT4CBT)

Interventions

  • BehavioralCognitive Behavioral Therapy (CBT4CBT)

    Participants will receive one therapist-led motivational interviewing/goal setting session followed by 7 sessions of computerized CBT4CBT.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants in Remission

    Remission is classified as the absence of DSM-5 cannabis use disorder symptoms (except cravings) as measured by semi-structured diagnostic interview.

    Time frame: Week 4

  2. Proportion of Participants in Remission

    Remission is classified as the absence of DSM-5 cannabis use disorder symptoms (except cravings) as measured by semi-structured diagnostic interview.

    Time frame: Week 8

  3. Proportion of Participants in Remission

    Remission is classified as the absence of DSM-5 cannabis use disorder symptoms (except cravings) as measured by semi-structured diagnostic interview.

    Time frame: Week 12

  4. Proportion of Participants in Remission

    Remission is classified as the absence of DSM-5 cannabis use disorder symptoms (except cravings) as measured by semi-structured diagnostic interview.

    Time frame: Week 16

  5. Proportion of Participants in Remission

    Remission is classified as the absence of DSM-5 cannabis use disorder symptoms (except cravings) as measured by semi-structured diagnostic interview.

    Time frame: Week 20

  6. Reduction in Cannabis Use Days

    Number of cannabis use days assessed via daily diaries during treatment, past 28 days

    Time frame: 8 weeks of treatment

  7. Reduction in Cannabis Use Episodes

    Number of cannabis use grams assessed via daily diaries during treatment, last 28 days

    Time frame: 8 weeks of treatment

07

Results

Posted Nov 12, 2026

Participant flow

Participant flow — Overall Study
MilestoneCognitive Behavioral Therapy - MalesCognitive Behavioral Therapy - Females
Started112112
Week 49194
Week 88689
Week 128282
Week 167981
Completed7879
Not completed3433

Outcome measures

PrimaryProportion of Participants in Remission

Remission is classified as the absence of DSM-5 cannabis use disorder symptoms (except cravings) as measured by semi-structured diagnostic interview.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Proportion of Participants in Remission
ParticipantsCognitive Behavioral Therapy - MalesCognitive Behavioral Therapy - Females
Proportion of Participants in Remission52
PrimaryProportion of Participants in Remission

Remission is classified as the absence of DSM-5 cannabis use disorder symptoms (except cravings) as measured by semi-structured diagnostic interview.

Time frame:
Week 8
Reported as:
Count of participants · Participants
Proportion of Participants in Remission
ParticipantsCognitive Behavioral Therapy - MalesCognitive Behavioral Therapy - Females
Proportion of Participants in Remission189
PrimaryProportion of Participants in Remission

Remission is classified as the absence of DSM-5 cannabis use disorder symptoms (except cravings) as measured by semi-structured diagnostic interview.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Proportion of Participants in Remission
ParticipantsCognitive Behavioral Therapy - MalesCognitive Behavioral Therapy - Females
Proportion of Participants in Remission219
PrimaryProportion of Participants in Remission

Remission is classified as the absence of DSM-5 cannabis use disorder symptoms (except cravings) as measured by semi-structured diagnostic interview.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Proportion of Participants in Remission
ParticipantsCognitive Behavioral Therapy - MalesCognitive Behavioral Therapy - Females
Proportion of Participants in Remission1714
PrimaryProportion of Participants in Remission

Remission is classified as the absence of DSM-5 cannabis use disorder symptoms (except cravings) as measured by semi-structured diagnostic interview.

Time frame:
Week 20
Reported as:
Count of participants · Participants
Proportion of Participants in Remission
ParticipantsCognitive Behavioral Therapy - MalesCognitive Behavioral Therapy - Females
Proportion of Participants in Remission2520
PrimaryReduction in Cannabis Use Days

Number of cannabis use days assessed via daily diaries during treatment, past 28 days

Time frame:
8 weeks of treatment
Reported as:
Mean · days
Reduction in Cannabis Use Days
daysCognitive Behavioral Therapy - MalesCognitive Behavioral Therapy - Females
Reduction in Cannabis Use Days21.0 ± 9.121.4 ± 6.8
PrimaryReduction in Cannabis Use Episodes

Number of cannabis use grams assessed via daily diaries during treatment, last 28 days

Time frame:
8 weeks of treatment
Reported as:
Mean · grams
Reduction in Cannabis Use Episodes
gramsCognitive Behavioral Therapy - MenCognitive Behavioral Therapy - Women
Reduction in Cannabis Use Episodes22.3 ± 28.915.6 ± 16.5

Adverse events

Collected over Adverse events are collected beginning as study enrollment until the end of follow-up at week 20.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cognitive Behavioral Therapy - Males0/112 (0%)0/112 (0%)27/112 (24.1%)
Cognitive Behavioral Therapy - Females0/112 (0%)1/112 (0.9%)36/112 (32.1%)
Most frequent serious events
Most frequent serious events
EventCognitive Behavioral Therapy - MalesCognitive Behavioral Therapy - Females
SinusitisInfections and infestations0/1121/112
Most frequent other events
Most frequent other events
EventCognitive Behavioral Therapy - MalesCognitive Behavioral Therapy - Females
Viral Upper Respiratory Tract InfectionsInfections and infestations16/11221/112
sore throatInfections and infestations4/1128/112
Nasal CongestionInfections and infestations5/1128/112
Influenza Like IllnessInfections and infestations6/1126/112

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cognitive Behavioral Therapy - MalesCognitive Behavioral Therapy - FemalesTotal
Mean32.6 ± 1130.2 ± 11.631.4 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Cognitive Behavioral Therapy - MalesCognitive Behavioral Therapy - FemalesTotal
Female0112112
Male1120112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cognitive Behavioral Therapy - MalesCognitive Behavioral Therapy - FemalesTotal
American Indian or Alaska Native000
Asian325
Native Hawaiian or Other Pacific Islander000
Black or African American201838
White8081161
More than one race51015
Unknown or Not Reported415
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cognitive Behavioral Therapy - MalesCognitive Behavioral Therapy - FemalesTotal
Hispanic or Latino9918
Not Hispanic or Latino103103206
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Cognitive Behavioral Therapy - MalesCognitive Behavioral Therapy - FemalesTotal
United States112112224
Grams of Cannabis use
Grams of Cannabis use(grams)Cognitive Behavioral Therapy - MalesCognitive Behavioral Therapy - FemalesTotal
Mean63.4 ± 178.347.6 ± 5754.9 ± 132.2
Cannabis Use Days
Cannabis Use Days(days)Cognitive Behavioral Therapy - MalesCognitive Behavioral Therapy - FemalesTotal
Mean26.2 ± 6.526.7 ± 5.726.3 ± 6.3
08

Study locations

1 site
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Investigators support data sharing as essential for scientific advancement. It is expected that primary outcome papers will be completed and submitted to appropriate peer-reviewed scientific journals within 180 days of data lock. Requests for data from this project by individuals outside of the research team will be reviewed by the team following data lock. Data sharing will adhere to all provisions of the Health Insurance Portability and Accountability Act (HIPAA) and the rights and privacy of people who participate in research will be protected at all times. The requesting Investigator must specify the subset of variables needed or provide a detailed justification of why the complete dataset is absolutely necessary. Data made available to other investigators will be free of identifiers that would permit linkages to individual research participants and variables that could lead to deductive disclosure of the identity of individual subjects.

Supporting information: Study protocol, Informed consent form

Time frame: Requests for data from this project by individuals outside of the research team will be reviewed by the team 180 days after study completion.

Access criteria: The requesting Investigator must specify the subset of variables needed. Data made available to other investigators will be free of identifiers that would permit linkages to individual research participants and variables that could lead to deductive disclosure of the identity of individual subjects. Data will be shared via CSV file or other requested formats, if the study team is able to accommodate the alternative requested format.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Oct 2025, 47 months.

Results were first posted in Nov 2026, 1 year after primary completion.

Of 143 non-industry interventional studies with no phase under Lymphoma, Follicular, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 47. This study's 47 months is above that.

Counting every sponsor, half of 167 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2021
First posted
Jul 16, 2021
StartActual
Nov 15, 2021
Primary completionActual
Oct 27, 2025
CompletionActual
Oct 27, 2025
Results first posted
Nov 12, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 12, 2026
Eligibility
Revised
Nov 12, 2026
Interventions
Arm changed Cognitive Behavioral Therapy - Men→Cognitive Behavioral Therapy - Males; Cognitive Behavioral Therapy - Women→Cognitive Behavioral Therapy - Females
Nov 12, 2026
Primary outcomes
7 edited
What changed in the outcomes
  • EditedProportion of participantsParticipants in remissionRemissionTime frame: Week 4
  • EditedProportion of participantsParticipants in remissionRemissionTime frame: Week 8
  • EditedProportion of participantsParticipants in remissionRemissionTime frame: Week 12
  • EditedProportion of participantsParticipants in remissionRemissionTime frame: Week 16
  • EditedProportion of participantsParticipants in remissionRemissionTime frame: Week 20
  • EditedReduction in cannabis use daysCannabis Use DaysTime frame: 8 weeks of treatment
  • EditedReduction in cannabis use episodesCannabis Use EpisodesTime frame: 8 weeks of treatment
Nov 12, 2026
Documents
Show all 1 update
  1. Nov 12, 2026
    Results posted
    Eligibility Revised
    Primary outcomes 7 edited
    What changed in the outcomes
    • EditedProportion of participantsParticipants in remissionRemissionTime frame: Week 4
    • EditedProportion of participantsParticipants in remissionRemissionTime frame: Week 8
    • EditedProportion of participantsParticipants in remissionRemissionTime frame: Week 12
    • EditedProportion of participantsParticipants in remissionRemissionTime frame: Week 16
    • EditedProportion of participantsParticipants in remissionRemissionTime frame: Week 20
    • EditedReduction in cannabis use daysCannabis Use DaysTime frame: 8 weeks of treatment
    • EditedReduction in cannabis use episodesCannabis Use EpisodesTime frame: 8 weeks of treatment
    Interventions Arm changed Cognitive Behavioral Therapy - Men→Cognitive Behavioral Therapy - Males; Cognitive Behavioral Therapy - Women→Cognitive Behavioral Therapy - Females
    + 5 other changes: verification date, responsible party, oversight details, design details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04964739
Responsible party
Rachel Tomko (Associate Professor-Faculty, Medical University of South Carolina) — Principal investigator
First posted
Jul 16, 2021
Start date
Nov 15, 2021
Primary completion
Oct 27, 2025
Completion
Oct 27, 2025
Results posted
Nov 12, 2026
Last update
Nov 12, 2026

Study contacts

Rachel L Tomko, PhD
principal investigator · Medical University of South Carolina
Aimee L McRae-Clark, PharmD
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion